临床药师参与1例妊娠合并宫颈癌新辅助化疗的药学实践被引量：1

Participation of clinical pharmacists in the treatment of one patient with cervical cancer in pregnant receiving neoadjuvant chemotherapy

原文传递

导出

摘要对于妊娠合并宫颈癌要求继续妊娠者,处理起来往往非常棘手,迄今全球关于妊娠合并宫颈癌尚无统一的治疗方案,也无相应的药学监护模式。本文通过报道临床药师参与1例妊娠合并ⅠB2期宫颈癌新辅助化疗会诊病例的方案制订和实施个体化药学监护,患者宫颈癌病灶由4.5 cm×4 cm缩小至2cm×2 cm,获得手术机会并顺利分娩出一对龙凤胎,为临床药师在妊娠合并宫颈癌患者新辅助化疗全程管理中的药学监护模式提供借鉴。 It is difficult to deal with the pregnant with cervix cancer patient who wants to continue pregnancy. So far, there has been no agreement on the treatment and pharmaceutical care model for pregnancy with cervical cancer worldwide. Clinical pharmacists participated in the treatment of stage IB2 cervical cancer during pregnancy with neoadjuvant chemotherapy and provided individualized pharmaceutical care. At last, the cervical cancer lesions were reduced from 4.5 cm×4 cm to 2 cm×2 cm, surgery proved successful and healthy twins delivered. We offered experiences in the patterns of pharmaceutical care in the management of neoadjuvant chemotherapy for pregnant women with cervical cancer.

作者黄振聪李晓云刘文辉李金卓廖益喜严汝庆 HUANG Zhen-cong;LI Xiao-yun;LIU Wen-hui;LI Jin-zhuo;LIAO Yi-xi;YAN Ru-qing(Department of Pharmacy,People's Hospital of Hezhou Guangxi,Hezhou Guangxi 542899;Department of Pharmacy,Seeond Xiangya Hospital,Central South University,Changsha 410008;Department of Radiation Oneology,People's Hospital of Hezhou Guangxi,Hezhou Guangxi 542899)

机构地区广西贺州市人民医院药学部中南大学湘雅二医院药学部广西贺州市人民医院肿瘤放疗科

出处《中南药学》 CAS 2019年第1期133-135,共3页 Central South Pharmacy

关键词妊娠合并宫颈癌新辅助化疗药学监护 cervical cancer in pregnancy neoadjuvant chemotherapy pharmaceutical care

分类号 R473.31 [医药卫生—护理学]

引文网络
相关文献

参考文献2

1宫颈癌及癌前病变规范化诊疗指南(试行)[J].中国医学前沿杂志（电子版）,2013,5(8):40-49. 被引量：291
2李小平,宗晓楠.妊娠合并宫颈癌新辅助化疗现状[J].中国实用妇科与产科杂志,2016,32(9):838-841. 被引量：10

二级参考文献35

1Jemal A,Siegel R,Ward E. Cancer Statistics,2007[J].{H}CA-A Cancer Journal for Clinicians,2007.43-66.
2Howe HL,Wu X,Ries LA. Annual report to the nation on the status of cancer,1975-2003,featuring cancer among U.S.Hispanic/Latino populations[J].{H}CANCER,2006,(08):1711-1742.
3Sherman ME,Wang SS,Carreon J. Mortality trends for cervical squamous and adenocarcinoma in the United States.Relation to incidence and survival[J].{H}CANCER,2005,(06):1258-1264.
4Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005.74-108.
5Kamangar F,Dores GM,Anderson WF. Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world[J].{H}Journal of Clinical Oncology,2006,(14):2137-2150.
6Villa LL,Costa RL,Petta CA. Prophylactic quadrivalent human papillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controlled multicentre phase II efifcacy trial[J].{H}LANCET ONCOLOGY,2005.271-278.
7Ault KA,Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2,grade 3,and adenocarcinoma in situ:a combined analysis of four randomised clinical trials[J].{H}LANCET,2007,(9576):1861-1868.
8FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].{H}New England Journal of Medicine,2007,(19):1915-1927.
9Arbyn M,Dillner J. Review of current knowledge on HPV vaccination：an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening[J].{H}Journal of Clinical Virology,2007,(03):189-197.
10American College of Obstetricians and Gynecologists. ACOG practice bulletin.Diagnosis and treatment of cervical carcinomas.Number 35,May 2002[J].{H}International Journal of Gynecology & Obstetrics,2002.79-91.